AR7

AR7 (80306-38-3) is an atypical retinoid which acts as an RARα antagonist and activates chaperone-mediated autophagy (CMA) via an RAR-dependent pathway.1 Downstream signaling results in an increase of LAMP-2A expression.1 Cells pretreated with AR7 had markedly improved viability in a paraquat-induced oxidative stress model.1 AR7 stimulated CMA and attenuated accumulation of SNCA oligomers in prolonged cultures of mutant cortical neurons2 indicating that CMA activation may be a viable disease modifying strategy in Parkinson’s disease3. A targetome analysis of AR7-induced CMA in cancer cells has been performed.4

AR 7 is a CMA booster. Used in biological study of chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives.

[1] JAIME ANGUIANO. Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives[J]. Nature chemical biology, 2013, 9 6: 374-382. DOI:10.1038/nchembio.1230
[2] PHILIP WING-LOK HO. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).[J]. Autophagy, 2020, 16 2: 347-370. DOI:10.1080/15548627.2019.1603545
[3] SRINIVASA REDDY BONAM  Sylviane M  Christine Tranchant. Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease.[J]. ACS Applied Materials & Interfaces, 2021. DOI:10.3390/cells10123547
[4] YUQING HAO. Targetome analysis of chaperone-mediated autophagy in cancer cells.[J]. Autophagy, 2019: 1558-1571. DOI:10.1080/15548627.2019.1586255